
Stock Details
CEO
Arnon Rosenthal
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
175
Address
131 Oyster Point Boulevard, South San Francisco, CA, 94080
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Top Competitors
Income Statement
Financials
Revenue Estimates
EPS Estimates
Net Income Estimates
Price target for Alector, Inc. $2.13
$0
$249.61
$325
EPS
Revenue
Institutional Holder
Loading institutional holder data...
Congress Tracker
Showing 0 of 0 results
Insider Trading of Key Employees
Showing 0 of 0 results